抄録
Human herpesvirus 6 (HHV-6) is ubiquitous in the human population and causes exanthem subitum, a benign disease seen in infancy. The virus remains latent in the body after primary infection, and reactivates in immunocompromised patients. Infection occurs in nearly half of all bone marrow or solid organ transplant recipients 2-3 weeks following the procedure. It has been suggested that the viral infection and activation result in clinical symptoms including fever, skin rash, pneumonia, bone marrow suppression, encephalitis, and rejection. In order to control the viral infection, several studies investigating the route of viral transmission and diagnostic procedures have been carried out.
| 元の言語 | English |
|---|---|
| ページ（範囲） | 11-18 |
| ページ数 | 8 |
| ジャーナル | Nagoya journal of medical science |
| 巻 | 64 |
| 発行部数 | 1-2 |
| 出版物ステータス | Published - 01-01-2001 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
これを引用
}
Human herpesvirus 6 infection in transplantation. / Yoshikawa, Tetsushi.
：: Nagoya journal of medical science, 巻 64, 番号 1-2, 01.01.2001, p. 11-18.研究成果: Review article
TY - JOUR
T1 - Human herpesvirus 6 infection in transplantation.
AU - Yoshikawa, Tetsushi
PY - 2001/1/1
Y1 - 2001/1/1
N2 - Human herpesvirus 6 (HHV-6) is ubiquitous in the human population and causes exanthem subitum, a benign disease seen in infancy. The virus remains latent in the body after primary infection, and reactivates in immunocompromised patients. Infection occurs in nearly half of all bone marrow or solid organ transplant recipients 2-3 weeks following the procedure. It has been suggested that the viral infection and activation result in clinical symptoms including fever, skin rash, pneumonia, bone marrow suppression, encephalitis, and rejection. In order to control the viral infection, several studies investigating the route of viral transmission and diagnostic procedures have been carried out.
AB - Human herpesvirus 6 (HHV-6) is ubiquitous in the human population and causes exanthem subitum, a benign disease seen in infancy. The virus remains latent in the body after primary infection, and reactivates in immunocompromised patients. Infection occurs in nearly half of all bone marrow or solid organ transplant recipients 2-3 weeks following the procedure. It has been suggested that the viral infection and activation result in clinical symptoms including fever, skin rash, pneumonia, bone marrow suppression, encephalitis, and rejection. In order to control the viral infection, several studies investigating the route of viral transmission and diagnostic procedures have been carried out.
UR - http://www.scopus.com/inward/record.url?scp=0035351337&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035351337&partnerID=8YFLogxK
M3 - Review article
C2 - 11486597
AN - SCOPUS:0035351337
VL - 64
SP - 11
EP - 18
JO - Nagoya Journal of Medical Science
JF - Nagoya Journal of Medical Science
SN - 0027-7622
IS - 1-2
ER -